SG Americas Securities LLC Sells 10,113 Shares of LivaNova PLC (NASDAQ:LIVN)

SG Americas Securities LLC lowered its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 78.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,844 shares of the company's stock after selling 10,113 shares during the period. SG Americas Securities LLC's holdings in LivaNova were worth $149,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Fifth Third Bancorp raised its position in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after purchasing an additional 332 shares during the period. Hexagon Capital Partners LLC increased its holdings in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after buying an additional 370 shares during the period. Lazard Asset Management LLC bought a new stake in shares of LivaNova in the 1st quarter valued at about $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova in the 2nd quarter valued at about $88,000. Finally, Acadian Asset Management LLC purchased a new stake in LivaNova during the 1st quarter valued at about $94,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Needham & Company LLC boosted their price objective on LivaNova from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, July 31st. Stifel Nicolaus upped their price target on shares of LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Robert W. Baird raised shares of LivaNova from a "neutral" rating to an "outperform" rating and increased their price target for the company from $55.00 to $66.00 in a research report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective on the stock. Finally, Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $69.83.

LivaNova Stock Up 0.2 %

Shares of NASDAQ:LIVN traded up $0.08 during trading on Friday, hitting $53.00. The stock had a trading volume of 248,579 shares, compared to its average volume of 618,329. The company has a market capitalization of $2.87 billion, a PE ratio of -88.33 and a beta of 1.00. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The firm's fifty day moving average is $50.54 and its 200 day moving average is $53.20. LivaNova PLC has a 12 month low of $42.75 and a 12 month high of $64.47.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.15. The firm had revenue of $318.60 million for the quarter, compared to analysts' expectations of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. Analysts anticipate that LivaNova PLC will post 2.58 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.